This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Expression of PGE2, Bcl-2 and Bax in carcinogenesis of colorectal mucosa
Miao Ouyang, Gui-Ying Zhang, Mei-Hua Xu
Miao Ouyang, Gui-Ying Zhang, Mei-Hua Xu, Department of Digestion, Xiangya Hospital, the Central South University, Changsha 410008, Hunan Province, China
Correspondence to: Miao Ouyang, Department of Digestion, Xiangya Hospital, the Central South University, Changsha 410008, Hunan Province, China.
Received: December 30, 2004 Revised: January 15, 2005 Accepted: February 26, 2005 Published online: June 15, 2005
AIM: To investigate the expression of PGE2, Bcl-2 and Bax in the carcinogenesis of colorectal mucosa and the relationship between them.
METHODS: The expression of PGE2, Bcl-2 and Bax were detected in 15 normal colorectal mucous membrane (NCM), 20 chronic colonitis (CHC), 30 colorectal adenoma (CAA), 50 colorectal cancer (CC)and 50 cancer adjacent (CAT) tissues by DAB immunohistochemical staining. The correlations among PGE2, Bcl-2 and Bax expression as well as the clinical and pathological characteristics were analyzed.
RESULTS: The rates of PGE2 expression in NCM, CHC, CAT, CAA and CC tissues were 6.67%, 10%, 40%, 56.7% and 90% respectively and manifested an ascending trend. The rates of Bcl-2 expression in the five groups were 6.67%, 10%, 38%, 46.7%, and 76% respectively and also showed an ascending trend. The rates of Bax expression in the five groups was 86.67%, 75%, 78%, 76.7% and 82% respectively and there was no significant difference among the five groups (P>0.05). However, the positive degree in NCM, CA and CC group exhibited a descending trend (P<0.05). The expressions of PGE2, Bcl-2 and Bax in human CC were not associated with sex, age and the size of tumor (P>0.05). A positive correlation was noted between expression of PGE2 and Bcl-2 in CC tissue (r = 0.532, P<0.05). The same correlation also existed between Bax and Bcl-2 (r = 0.653, P<0.05). The rates of PGE2, Bcl-2 and Bax expression in highly and moderately differentiated CC were significantly higher than those in lowly differentiated one (100%, 88.9%, 85.2% vs 79.3%, 60.9%, 78.3%; P<0.05). The expression of Bcl-2 was significantly higher in Duke's A, B stage than that in Duke's C, D (90%, 77.8% vs 60%, 57.2%; P<0.05).
CONCLUSION: The expression of PGE2 and Bcl-2 increases while that of Bax decreases with the occurrence and development of CC, which indicates that PGE2 and Bcl-2 play important roles in the carcinogenesis and development of CC. At the same time, there is a positive relationship between PGE2 and Bcl-2.
Key Words: PGE2; Bcl-2; Bax; Colorectal cancer
Citation: Ouyang M, Zhang GY, Xu MH. Expression of PGE2, Bcl-2 and Bax in carcinogenesis of colorectal mucosa. Shijie Huaren Xiaohua Zazhi 2005; 13(11): 1305-1309
Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes B2 or C colon cancer: a North Central Cancer Treatment Group Study.J Clin Oncol. 2004;22:1572-1582.
[PubMed] [DOI]
Liu WH, Kaur M, Wang G, Zhu P, Zhang Y, Makrigiorgos GM. Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cells and tumors.Cancer Res. 2004;64:2544-2551.
[PubMed] [DOI]
Cai J, Chen Y, Murphy TJ, Jones DP, Sartorelli AC. Role of caspase activation in butyrate-induced terminal differentiation of HT29 colon carcinoma cells.Arch Biochem Biophys. 2004;424:119-127.
[PubMed] [DOI]
Palozza P, Serini S, Torsello A, Di Nicuolo F, Maggiano N, Ranelletti FO, Wolf FI, Calviello G. Mechanism of activation of caspase cascade during beta-carotene-induced apoptosis in human tumor cells.Nutr Cancer. 2003;47:76-87.
[PubMed] [DOI]
Kouraklis G, Kakisis J, Theoharis S, Tzonou A, Glinavou A, Raftopoulos J, Karatzas G. Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.Dig Dis Sci. 2003;48:2284-2289.
[PubMed] [DOI]
Liu CY, Lai YY, Lo CJ. Levamisole modulates prostaglandin E2 production and cyclooxygenase II gene expression in human colonic cancer cells.J Surg Res. 2004;117:223-231.
[PubMed] [DOI]
Levy P, Robin H, Bertrand F, Kornprobst M, Capeau J. Butyrate-treated colonic Caco-2 cells exhibit defective ntegrin-mediated signaling together with increased apoptosis and differentiation.J Cell Physiol. 2003;197:336-347.
[PubMed] [DOI]
Heerdt BG, Houston MA, Wilson AJ, Augenlicht LH. The intrinsic mitochondrial membrane potential (Deltapsim) is associated with steady-state mitochondrial activity and the extentto which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis.Cancer Res. 2003;63:6311-6319.
[PubMed] [DOI]
Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas.Oncogene. 1994;9:3367-3370.
[PubMed] [DOI]
Xu LH, Deng CS, Zhu YQ, Liu SQ. [Synergistic effect of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and doxorubicin on human colon cancer SW480 cells].Ai Zheng. 2003;22:816-820.
[PubMed] [DOI]
Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG, Schuppan D. Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells.Int J Oncol. 2003;23:751-756.
[PubMed] [DOI]
Ito T, Akao Y, Yi H, Ohguchi K, Matsumoto K, Tanaka T, Iinuma M, Nozawa Y. Antitumor effect of resveratrol oligomers against human cancer cell ines and the molecular mechanism of apoptosis induced by vaticanol C.Carcinogenesis. 2003;24:1489-1497.
[PubMed] [DOI]
Farah M, Parhar K, Moussavi M, Eivemark S, Salh B 5,6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-alpha-mediated apoptosis. Am J Physiol Gastrointest Liver Physiol. 2003;285:G919-928.
[PubMed] [DOI]
Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, Roller PP, Wang S, Yang D. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells.Biochem Pharmacol. 2003;66:93-103.
[PubMed] [DOI]
Hoetelmans RW, Vahrmeijer AL, Mulder GJ, van de Velde CJ, Nagelkerke JF, van Dierendonck JH. Bcl-2 overexpression does not prevent but retards adriamycin toxicity in CC531 colon carcinoma cells.Chemotherapy. 2003;49:309-315.
[PubMed] [DOI]
Perrone G, Vincenzi B, Santini D, Verzi A, Tonini G, Vetrani A, Rabitti C. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer.Cancer Lett. 2004;208:227-234.
[PubMed] [DOI]
Godlewski MM, Gajkowska B, Lamparska-Przybysz M, Motyl T. Colocalization of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon adenocarcinoma COLO 205 cells.Anticancer Drugs. 2002;13:1017-1029.
[PubMed] [DOI]
Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H. Inhibition of angiotensin II activity enhanced the antitumor effectof cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.Cancer Res. 2003;63:6726-6734.
[PubMed] [DOI]
Yasumaru M, Tsujii M, Tsuji S. [Combination therapies using cyclooxygenase-2 inhibitors and angiotensin-converting enzyme inhibitors in colon carcinogenesis].Nippon Rinsho. 2003;61 Suppl 7:510-514.
[PubMed] [DOI]
Hong MY, Chapkin RS, Davidson LA, Turner ND, Morris JS, Carroll RJ, Lupton JR. Fish oil enhances targeted apoptosis during colon tumor initiation in part by downregulating Bcl-2.Nutr Cancer. 2003;46:44-51.
[PubMed] [DOI]
Pai R, Nakamura T, Moon WS, Tarnawski AS. Related Articles, Links Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.FASEB J. 2003;17:1640-1647.
[PubMed] [DOI]
Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.Cancer. 1996;77:255-264.
[PubMed] [DOI]
Yu HG, Huang JA, Yang YN, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells.Regul Pept. 2003;114:101-107.
[PubMed] [DOI]
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy.Nat Med. 2002;8:289-293.
[PubMed] [DOI]
Sherratt PJ, McLellan LI, Hayes JD. Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents.Biochem Pharmacol. 2003;66:51-61.
[PubMed] [DOI]
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.Cancer Res. 1998;58:362-366.
[PubMed] [DOI]